On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009.  Nonetheless, at the start of the year...
Read More »

In January 2007, Amgen, Inc. (AMGN) obtained an option from Cytokinetics, Inc. (CYTK) to commercialize a novel small-molecule therapeutic product candidate that activates cardiac myosin with potential applications in the treatment of heart failure.  Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy...
Read More »